Quanterix

Quanterix Corporation is developing a novel platform for single-molecule analysis that will bring an unprecedented level of sensitivity, precision, and assay robustness to clinical diagnostics, drug development, and life science research. Their unique approach permits rapid quantification and analysis of individual proteins and small molecules within complex biological samples, enabling us to address a variety of unmet medical needs.

The company’s ultra-sensitive detection solution, Simoa, has the potential to change the way in which healthcare is provided today by giving researchers the ability to closely examine the role of biomarkers in the continuum of health to disease. Quanterix’s technology is designed to enable much earlier disease detection, better prognosis, and precise treatment methods to improve the quality of life and longevity of the population for generations to come.

Quanterix headquartered in United States, North America, operates in the Biotechnology, Life Science, Health Care, Pharmaceutical, Health Diagnostics sector. The company focuses on Biotechnology and has secured $128.0B in funding across 240 round(s). With a team of 251-500 employees, Quanterix is actively contributing to advancements in Biotechnology. Their latest funding round, Series A - Quanterix, raised $15.0M. Discover more about their projects, partnerships, and impact on our platform.